Pfizer Decides Not To Challenge AbbVie's Humira Biosimilar Patents
Pfizer is the seventh company to enter licensing agreement with AbbVie; it has completed development program for its adalimumab candidate.
You may also be interested in...
Getting seven top pharma leaders in the same room, required to answer tough questions on drug pricing, is rare. Members of the Senate Finance Committee got that opportunity recently, but there are some questions our Pink Sheet reporters think they missed.
Sen. Cornyn recommended the Judiciary Committee initiate an inquiry into drug patents after a back-and-forth with AbbVie CEO Gonzalez over the Humira patent estate at the drug pricing hearing.
Marketing applications for Teva’s migraine prevention CGRP inhibitor, fremanezumab, and CTI BioPharma’s myelofibrosis treatment, pacritinib, are among a number of submissions scheduled for discussion this week by the European Medicines Agency’s drug evaluation committee, the CHMP.